Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Ivonne Regel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0206-4441; OpenAlex author ID A5026049234. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 4 papers · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 20

  1. STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.01.031↗
  2. Unveiling sex differences in pancreatic ductal adenocarcinoma: Current evidence and future directions (Review). Co-author DOI 10.3892/ijo.2026.5848↗
  3. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  4. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes. Last author DOI 10.3892/ijo.2024.5614↗
  5. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. Co-author DOI 10.1007/s00432-023-05100-7↗
  6. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  7. Nutrient Scavenging From Muscle Cells: A Survival Strategy of Pancreatic Cancer Cells Ends in Cachexia. Co-author DOI 10.1053/j.gastro.2022.07.069↗
  8. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review. Co-author DOI 10.1186/s13014-022-02076-5↗
  9. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenoc… Co-author DOI 10.1053/j.gastro.2021.05.055↗
  10. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  11. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer. Co-author DOI 10.3390/cancers12041024↗
  12. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Last author DOI 10.3390/cancers12113234↗
  13. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  14. Pathobiology of pancreatic cancer: implications on therapy. Co-author DOI 10.1586/14737140.2016.1129276↗
  15. Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells. First author DOI 10.18632/oncotarget.6717↗
  16. RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-14-1327↗
  17. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0358-5↗
  18. Erratum to: Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0401-6↗
  19. Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.5168↗
  20. Complexity of molecular alterations impacts pancreatic cancer prognosis. Co-author DOI 10.4251/wjgo.v5.i1.1↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julia V. Mayerle · 9 shared papers, 2018–2026 · strength 1.42
  2. Ujjwal Mukund Mahajan · 5 shared papers, 2018–2024 · strength 0.55
  3. Georg Beyer · 5 shared papers, 2018–2022 · strength 0.51
  4. Jorg H. Kleeff · 7 shared papers, 2015–2024 · strength 0.50
  5. Daniel Öhlund · 2 shared papers, 2020–2026 · strength 0.44
  6. Frank Ulrich Weiß · 4 shared papers, 2018–2022 · strength 0.36
  7. Markus M. Lerch · 4 shared papers, 2018–2022 · strength 0.36
  8. Simone Benitz · 3 shared papers, 2016–2024 · strength 0.32
  9. Sophie Rauschenberg · 1 shared paper, 2026 · strength 0.32
  10. Lina Aguilera Munoz · 1 shared paper, 2026 · strength 0.32
  11. Matthias J. Löhr · 1 shared paper, 2026 · strength 0.32
  12. Elisabetta Goni · 3 shared papers, 2018–2022 · strength 0.26
  13. Marlies Vornhülz · 2 shared papers, 2022 · strength 0.26
  14. Simon Sirtl · 2 shared papers, 2022–2023 · strength 0.25
  15. Christoph W. Michalski · 5 shared papers, 2015–2016 · strength 0.23
  16. Ignazio Piseddu · 1 shared paper, 2026 · strength 0.21
  17. Veit Hornung · 1 shared paper, 2026 · strength 0.21
  18. Sebastian Kobold · 1 shared paper, 2026 · strength 0.21
  19. Anne Marie Senz · 1 shared paper, 2026 · strength 0.21
  20. Waldemar H. Uhl · 2 shared papers, 2021–2022 · strength 0.21
  21. Fritz Klein · 2 shared papers, 2021–2022 · strength 0.21
  22. Robert Grützmann · 2 shared papers, 2021–2022 · strength 0.21
  23. Christian P. Pilarsky · 2 shared papers, 2021–2022 · strength 0.21
  24. Marius Distler · 2 shared papers, 2021–2022 · strength 0.21
  25. Alexandr V. Bazhin · 2 shared papers, 2018–2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.